Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Withdrawn 3Completed 3Unknown 2Terminated 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Rectal Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Hydralazine × Clear all
NCT02446652 2025-05-29

Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer

National Institute of Cancerología

Phase 3 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

NCT00575640 2015-03-04

Hydralazine as a Demethylating Agent in Rectal Cancer

University of Arkansas

Phase 1/2 Withdrawn
Gastrointestinal

Rectal Neoplasms

NCT00575978 2015-03-04

Hydralazine as Demethylating Agent in Breast Cancer

University of Arkansas

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡